COVID-myriadrbm

IFN-α, IFN-β, & IFN-λ
Ultrasensitive Immunoassays

Applications for Viral Pneumonia Including COVID-19

Three consecutive papers with a concise “Perspectives” piece summarizing the reports were published in the August 7, 2020 issue of Science magazine.  The work sheds new light on the importance of Type I (IFN-α & IFN-β) and Type III (IFN-λ or IL-29) interferons for viral pneumonia including severe COVID-19 disease.

Myriad RBM has ultrasensitive immunoassays for all of these proteins available from our CLIA-certified laboratory.

The first two papers (Broggi et al. & Major et al.) describe the mechanisms by which IFN-λ responses contribute to pathogenesis in viral pneumonias and the third paper (Hadjab et al.) shows that critical COVID-19 patients have reduced IFN responses paired with a proinflammatory response; including the possibility that IFN-α and IFN-β plasma/serum levels are predictive biomarkers for COVID-19 Cytokine Storm.

 

Publications

Perspectives: Interferon responses in viral pneumonias. (2020) Grajales-Reyes G & Colonna M. Science 369(6504):626-627.

Type III interferons disrupt the lung epithelial barrier upon viral recognition. (2020) Broggi A, et al. Science 369(6504):706-712.

Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Major J, et al. Science 369(6504):712-717.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Hadjadj J, et al. Science 369(6504):718-724.
Recent coverage of the Hadjadj J, et al. article in BioSpace.

Myriad RBM, your source for Type I (IFN-α & IFN-β), Type II (IFN-γ), and Type III (IFN-λ or IL-29) Interferon ultrasensitive immunoassay testing needs in a CLIA-certified laboratory.